JPH0326166B2 - - Google Patents

Info

Publication number
JPH0326166B2
JPH0326166B2 JP58181629A JP18162983A JPH0326166B2 JP H0326166 B2 JPH0326166 B2 JP H0326166B2 JP 58181629 A JP58181629 A JP 58181629A JP 18162983 A JP18162983 A JP 18162983A JP H0326166 B2 JPH0326166 B2 JP H0326166B2
Authority
JP
Japan
Prior art keywords
hydrocarbon group
carbon atoms
vesicles
ion
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58181629A
Other languages
Japanese (ja)
Other versions
JPS6072831A (en
Inventor
Hiromichi Takahashi
Kaoru Tsujii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP58181629A priority Critical patent/JPS6072831A/en
Priority to GB08422628A priority patent/GB2147263B/en
Priority to DE19843435516 priority patent/DE3435516A1/en
Priority to FR8414910A priority patent/FR2552679B1/en
Publication of JPS6072831A publication Critical patent/JPS6072831A/en
Publication of JPH0326166B2 publication Critical patent/JPH0326166B2/ja
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明はベシクル用組成物に関し、更に詳細に
は長期間に渡つて安定なベシクルを調製すること
のできるベシクル用組成物に関する。 生体膜の重要な構成成分であるリン脂質、特に
レシチンが水中においてリポゾームと呼ばれる二
重膜中空小胞体を形成することは既によく知られ
ている。このリポゾームは、中空脂質二重膜球で
あり、内腔に種々の化学物質を包含することがで
きる等その構造が赤血球に酷似しているため、赤
血球のモデルあるいは細胞モデルとして研究さ
れ、生体膜研究に重要な役割りを果たしている。 また、近年、このリポゾームは薬物の生体内運
搬体として注目されている。すなわち、内腔に
種々の化学物質を包含することのできるリポゾー
ムは一種のカプセルと見なすことができ、薬物を
リポゾーム内部に入れて投与すると、薬物の生体
内代謝が抑制され長期間生体内に留つて薬効を持
続したり(例えばFEBS Letters,36巻,3号,
292頁,1973年)、薬物の副作用、例えばアレルギ
ー性が抑制されたり(例えばFEBS Letters,45
巻,1号,71頁,1974年)、薬物の各種臓器への
分布が変化したりする(例えばEur.J.Biochem.,
47巻,179頁,1974年)ことが報告されている。
この様にリポゾームは薬物の生体内運搬体として
優れた諸性質を示すのであるが、中でも薬物の臓
器分布を変化させ得る性質は薬物を疾患臓器へ選
択的に作用させ得る可能性を有しており、所謂リ
ポゾームによる標的効果として注目を集めてい
る。例えば制癌剤は癌細胞のみならず健康な正常
細胞にも作用するため副作用の伴なうことが多い
が、制癌剤をリポゾームに入れて投与することに
より癌組織に選択的に作用させることができれば
極めて有用であると考えられる。実際、その様な
試みが良好な結果を得ている場合がある(例えば
日本癌学会講演要旨集,8頁,1976年)。 また二重膜部分にアルキルアミン等の適当な伝
導性物質を包埋し、リポゾームの内液に第2銅イ
オン等の光還元性物質を、リポゾームの外液にア
スコルビン酸等の光酸化性物質を入れ、これに光
を照射することにより二重膜に包埋した伝導性物
質の性質に応じて、特定のイオンを外液から内液
に濃縮することが可能であり、たとえば海水から
ある特定の元素イオンを取出して資源化すること
ができる。この様にリポゾームは薬物投与等に画
期的な新しい手法をもたらすものであるが、リポ
ゾームを形成し得るリン脂質は生体由来物質のた
めその化学構造が極めて制限されており各種機能
の付与に不便であること、また、比較的化学的安
定性に乏しいこと等の欠点があつた。 そこで、リン脂質リポゾームのかかる制約を取
り除くために、最近合成界面活性剤を原料とする
リポゾーム型小胞体、すなわちベシクルを形成せ
しめるための研究がなされ、現在までに数種類の
界面活性剤にベシクル形成能があることが確認さ
れている。そしてかかる界面活性剤のベシクルも
リポゾームと同様に、二重膜中空小胞体構造を有
しており、上記の薬物運搬体等に適用され得るも
のである。 しかしながら、これら界面活性剤のベシクル
は、いずれも界面活性剤のみを水中に分散せし
め、これに例えば超音波を照射することにより得
られるもので、そのベシクル構造が不安定であ
り、長期間の保存に耐えられないのが現状であ
る。例えば、本発明で用いるジアルキルジメチル
アンモニウム塩について叙上の方法でベシクルを
得てもベシクル構造は数日以内に壊れ、溶液は白
濁若しくはゲル状を呈するようになる。 したがつて、界面活性剤ベシクルを薬物運搬体
やその他の目的に利用するためにはこの安定性を
改善することが不可欠であり、そのための技術が
強く要望されているのが現状であつた。 斯る現状に鑑み、本発明者らは長期間に渡つて
安定なベシクルを得べく鋭意研究をおこなつた結
果、ベシクル形成能を有する特定の第四級アンモ
ニウム塩、ある種の界面活性剤及び水を配合した
系より得たベシクルは長期間に渡つて安定に存在
し得ることを見出し、本発明を完成した。 すなわち、本発明は次の2成分(A)及び(B)を含有
し、(A)成分と(B)成分の重量比が100:1〜100:
100であるベシクル用組成物を提供するものであ
る。 (A) 一般式() 式中、各記号は次のものを意味する。 R1及びR2:炭素数10〜24の炭化水素基 R3及びR4:炭素数1〜4の炭化水素基若しくは
ヒドロキシ炭化水素基又はベンジル基 X :第四級アンモニウムイオンの対イオンとな
るアニオン で表わされる二本鎖型第四級アンモニウム塩 (B) 一種又は二種以上の、次の式(a)〜(q) R6O(AO)oH (b) HO(AO)p(C3H6O)q(AO)rH (d) R6COO(AO)oR10 (g) R15NH(A)tCOOM (p) 式中、各記号は次のものを示す。 R5:炭素数1〜4の炭化水素基若しくはヒドロ
キシ炭化水素基又はベンジル基 R6:炭素数8〜36の炭化水素基 R7:炭素数5〜23の炭化水素基 R8、R9及びR13:水素原子又は炭素数6〜24のア
シル基(ただし、一分子中にR7とR8を両方含
む場合、そのうち少なくとも一方は水素原子で
ある) R11及びR12:水素原子又は炭素数6〜24の炭化
水素基(ただし、少なくとも一方は水素原子で
ある) R13:炭素数9〜23の炭化水素基 R14:炭素数1〜24の炭化水素基若しくはヒドロ
キシ炭化水素基又はベンジル基 R15、R16及びR17:炭素数1〜24の炭化水素基 A:炭素数2〜4のアルキレン基 M:アルカリ金属イオン、モノエタノールアンモ
ニウムイオン、ジエタノールアンモニウムイオ
ン又はトリエタノールアンモニウムイオン l,m及びn:0又は1〜150の整数 p,q及びr:1〜150の整数 t:1〜4の整数 X :前記と同じ で表わされる化合物群から選ばれた界面活性剤。 (A)成分である二本鎖型第四級アンモニウム塩が
ベシクルを形成することはすでに公知であり、例
えば特開昭53−134784号公報に開示され、また、
学術雑誌J.Am.Chem.Soc.,99巻,3860頁,
(1977年)J.Colloid Interface Sci.,65巻,1号,
155頁,(1978)J.Am.Chem.Soc.,101巻,4030
頁,(1979年)等に報告されている。しかしなが
ら、(A)成分に(B)成分を配合することによりベシク
ルが長期間安定に保たれることは全く知られてお
らず、このことは本発明者らの研究によつて初め
て明らかにされたものである。 本発明(A)成分の具体例としては、例えばジデシ
ルジメチルアンモニウム塩、ジドデシルジメチル
アンモニウム塩、ジテトラデシルジメチルアンモ
ニウム塩、ジヘキサデシルジメチルアンモニウム
塩、ジオクタデシルジメチルアンモニウム塩、ジ
エイコシルジメチルアンモニウム塩、ジデシル−
N−ヒドロキシエチル−N−メチルアンモニウム
塩、ジドデシル−N−ヒドロキシエチル−N−メ
チルアンモニウム塩、ジテトラデシル−N−ヒド
ロキシエチル−N−メチルアンモニウム塩、ジヘ
キサデシル−N−ヒドロキシエチル−N−メチル
アンモニウム塩、ジオクタデシル−N−ヒドロキ
シエチル−N−メチルアンモニウム塩、ジエイコ
シル−N−ヒドロキシエチル−N−メチルアンモ
ニウム塩等をあげることができる。また、(A)成分
の対イオンについては、特に制限はないが、ハロ
ゲンイオン、メチル硫酸イオン、エチル硫酸イオ
ンが好ましい。 また、本発明の(B)成分の界面活性剤は、ベシク
ルを安定に保つ作用を有するものと考えられてお
り、このうち(a)は陽イオン性界面活性剤に、(b)〜
(m)は非イオン性界面活性剤に、(n)〜(q)
は両性界面活性剤にそれぞれ属するものである。
これら(B)成分のうち、(b)〜(m)の非イオン性界
面活性剤に付加するアルキレンオキサイドとして
は、エチレンオキサイドが好ましい。 本発明のベシクル用組成物においては、(A)成分
と(B)成分の配合重量比が重要であり、(A)成分と(B)
成分の比が100:1〜100:100の範囲であること
が必要である。配合重量比がこの範囲を外れた場
合、ベシクルが生成しないか又はベシクルが生成
しても不安定となる。 本発明のベシクル用組成物を製造するには公知
の方法に従い、(A)成分及び(B)成分を、これら両方
を溶解し得る溶媒に溶解し、撹拌して均一とし、
次いで溶媒を除去すれば良い。 斯くして得られた本発明のベシクル用組成物か
らベシクルを得るには、ベシクル用組成物を水に
懸濁させ、これに超音波を照射すれば良い。しか
しながら、この方法のみに限らず、例えば水に可
溶なエタノールの様な溶媒にベシクル用組成物を
溶解させ、この水溶液を水中に強く射出する方法
や水溶性の界面活性剤で可溶化し、次いで透析で
その界面活性剤を除去しながら作成する方法等も
利用し、ベシクル溶液を得ることができる。 本発明のベシクル用組成物により調製されるベ
シクル溶液は、その濃度が1〜50重量%(以下単
に%で示す)が好ましく、より好ましくは5〜30
%である。溶液のベシクル濃度が50%を越えると
粘度が高くなり過ぎ、ベシクルの調製工程及びベ
シクルの使用時において不都合の生じることがあ
る。また、濃度が1%未満の場合、調製及び使用
には何ら支障はないが、ベシクル溶液の輪送費や
容器の面でコストが上昇し、経済的ではない。 このようにして調製されたベシクル溶液中のベ
シクルを確認するための現在知られている最も確
かな方法はネガテイヴ染色法による電子顕微鏡観
察である。ネガテイヴ染色法とはリンタングステ
ン酸や酢酸ウラニールによつてベシクルを形成し
得る界面活性剤等の親水基部分の電子密度を高く
し、その部分を黒く染色する方法である。本発明
においてはこの方法によつてベシクル生成を観察
した。ベシクルを含有するベシクル溶液は透明で
ありかつ流動性も良い。一方、前記化合物がベシ
クルとはならず多層状構造となつた場合の溶液は
ゲル状で白濁しかつ流動性も極めて不良である。
従がつて、ベシクルの安定性試験(後述)におい
ては、たとえば超音波法でベシクル溶液を作り、
該溶液の透明度と流動性を経時的に観察すること
によりベシクル用組成物の安定性を判定すること
ができる。また、ベシクルを確認するための補助
的な簡便法として、核磁気共鳴(NMR)法が知
られている。すなわち、1H−又は13C−NMRの緩
和時間もしくは吸収線幅は、ベシクルの場合とそ
うでない場合とで大きく異なる。つまり、ベシク
ルの場合は緩和時間が長くなり、吸収線幅は狭く
鋭くなる、一方、ベシクルでない場合は、緩和時
間が短く、吸収線幅は広くなる。しかしながら
NMR法では、ベシクルの特徴である二重膜構造
の存在を直接確認することができず、ベシクルの
存在の厳密な確認のためには、上記の電子顕微鏡
による観察を行うべきである。 次に実施例により本発明を更に詳しく説明する
が、本発明はかかる実施例に限定されるものでは
ない。 実施例 1 表−1に示す二本鎖型第四級アンモニウム塩と
各種界面活性剤とからベシクル用組成物を調製
し、ベシクルの生成及びその安定性を調べた。こ
の結果を表−1に示す。 〔ベシクル用組成物の調製〕 クロロホルムに溶解した二本鎖型第四級アンモ
ニウム塩10gと界面活性剤1gを混合し、均一に
なるまで撹拌した。次いでエバポレーターを用い
てクロロホルムを除去し、ベシクル用組成物の粉
末を得た。 〔ベシクルの生成及びその確認〕 得られたベシクル用組成物の粉末10gに対し、
水90gを加えて撹拌すると粘稠で白濁したゲル状
組成物となつた。このゲル状組成物を60℃に保
ち、100W、25KHzの超音波を約1時間照射した。
得られた溶液について、電子顕微鏡観察をおこな
い、ベシクルの生成を確認した。なお、ベシクル
の生成しているものは、ほぼ透明で流動性の良い
溶液となつていた。 〔ベシクルの安定性試験〕 上記の如くして得られたベシクル溶液を3カ月
間20℃の恒温槽で保存し、3カ月経過後の状態を
透明度及び流動性の面から製造直後の状態と比較
して安定性を評価した。なお、ベシクルの生成及
びその安定性についての評価基準は次の通りであ
る。 A:保存後の状態が製造直後と全く変わらず、ベ
シクル構造が完全に保持されている。 B:製造直後に比べわずかに増粘している程度で
あり、ベシクル構造がほぼ完全に保持されてい
る。 C:製造直後の溶液の増粘と白濁が著しく、ベシ
クル構造がほとんど存在しない。 D:製造直後の溶液が完全にゲル化白濁し、ベシ
クル構造の存在が全く認められない。 *:超音波照射を行つてもベシクルとはならな
い。
The present invention relates to a composition for vesicles, and more particularly to a composition for vesicles that can prepare vesicles that are stable over a long period of time. It is already well known that phospholipids, particularly lecithin, which are important constituents of biological membranes, form double-membrane hollow endoplasmic reticulum called liposomes in water. Liposomes are hollow lipid-layered spheres with a structure that closely resembles that of red blood cells, including the ability to contain various chemical substances within their lumens. It plays an important role in research. Furthermore, in recent years, liposomes have attracted attention as in vivo drug carriers. In other words, liposomes, which can contain various chemical substances in their lumens, can be considered a type of capsule, and when a drug is administered inside the liposome, the metabolism of the drug in the body is suppressed and it remains in the body for a long time. (e.g., FEBS Letters, Vol. 36, No. 3,
292, 1973), drug side effects, such as allergic reactions, may be suppressed (e.g., FEBS Letters, 45
Vol. 1, p. 71, 1974), and the distribution of drugs to various organs may change (e.g. Eur. J. Biochem.
47, p. 179, 1974).
As described above, liposomes exhibit a variety of excellent properties as in-vivo drug carriers, but among them, the property of being able to change the organ distribution of drugs has the potential to cause drugs to act selectively on diseased organs. This is attracting attention as a targeting effect by so-called liposomes. For example, anticancer drugs act not only on cancer cells but also on healthy normal cells, so they often have side effects. However, it would be extremely useful if the anticancer drug could be administered selectively to cancer tissues by encasing it in liposomes and administering it. It is thought that. In fact, such attempts have sometimes yielded good results (for example, Japanese Cancer Society Abstracts, p. 8, 1976). In addition, an appropriate conductive substance such as an alkylamine is embedded in the double membrane part, a photoreducing substance such as cupric ions is added to the internal liquid of the liposome, and a photooxidizing substance such as ascorbic acid is added to the external liquid of the liposome. By irradiating it with light, it is possible to concentrate specific ions from the external fluid into the internal fluid depending on the properties of the conductive substance embedded in the double membrane. For example, it is possible to concentrate specific ions from seawater into the internal fluid. It is possible to extract elemental ions and turn them into resources. In this way, liposomes bring a revolutionary new method for drug administration, etc. However, the phospholipids that can form liposomes are biologically derived substances, so their chemical structures are extremely limited, making it inconvenient to impart various functions. It also had drawbacks such as relatively poor chemical stability. Therefore, in order to eliminate this limitation of phospholipid liposomes, research has recently been conducted on forming liposome-type endoplasmic reticulum, that is, vesicles, using synthetic surfactants as raw materials, and to date, several types of surfactants have the ability to form vesicles. It has been confirmed that there is. Similar to liposomes, such surfactant vesicles also have a double membrane hollow vesicle structure, and can be applied to the above-mentioned drug carriers. However, these surfactant vesicles are obtained by dispersing only the surfactant in water and irradiating it with ultrasonic waves, for example, and the vesicle structure is unstable and cannot be stored for a long time. The current situation is that it cannot be tolerated. For example, even if vesicles are obtained using the method described above for the dialkyldimethylammonium salt used in the present invention, the vesicle structure breaks down within a few days, and the solution becomes cloudy or gel-like. Therefore, in order to utilize surfactant vesicles as drug carriers or for other purposes, it is essential to improve this stability, and there is currently a strong demand for technology for this purpose. In view of the current situation, the present inventors conducted intensive research to obtain stable vesicles over a long period of time, and as a result, found that certain quaternary ammonium salts, certain surfactants, and The present invention was completed based on the discovery that vesicles obtained from a system containing water can exist stably for a long period of time. That is, the present invention contains the following two components (A) and (B), and the weight ratio of component (A) and component (B) is 100:1 to 100:
100 of the composition for vesicles. (A) General formula () In the formula, each symbol means the following. R 1 and R 2 : Hydrocarbon group having 10 to 24 carbon atoms R 3 and R 4 : Hydrocarbon group having 1 to 4 carbon atoms, hydroxy hydrocarbon group, or benzyl group X : Becomes a counter ion to the quaternary ammonium ion Double-stranded quaternary ammonium salt (B) represented by an anion, one or more of the following formulas (a) to (q) R 6 O (AO) o H (b) HO (AO) p (C 3 H 6 O) q (AO) r H (d) R 6 COO (AO) o R 10 (g) R 15 NH (A) t COOM (p) In the formula, each symbol represents the following. R 5 : Hydrocarbon group having 1 to 4 carbon atoms, hydroxy hydrocarbon group or benzyl group R 6 : Hydrocarbon group having 8 to 36 carbon atoms R 7 : Hydrocarbon group having 5 to 23 carbon atoms R 8 , R 9 and R 13 : Hydrogen atom or acyl group having 6 to 24 carbon atoms (however, if one molecule contains both R 7 and R 8 , at least one of them is a hydrogen atom) R 11 and R 12 : Hydrogen atom or carbon Hydrocarbon group having 6 to 24 carbon atoms (at least one of them is a hydrogen atom) R 13 : Hydrocarbon group having 9 to 23 carbon atoms R 14 : Hydrocarbon group having 1 to 24 carbon atoms, hydroxy hydrocarbon group, or benzyl Groups R 15 , R 16 and R 17 : Hydrocarbon group having 1 to 24 carbon atoms A: Alkylene group having 2 to 4 carbon atoms M: alkali metal ion, monoethanol ammonium ion, diethanol ammonium ion or triethanol ammonium ion l, m and n: 0 or an integer of 1 to 150 p, q and r: an integer of 1 to 150 t: an integer of 1 to 4 X: a surfactant selected from the group of compounds represented by the same as above. It is already known that the double-stranded quaternary ammonium salt, component (A), forms vesicles, for example, as disclosed in JP-A-53-134784;
Academic journal J.Am.Chem.Soc., volume 99, page 3860,
(1977) J. Colloid Interface Sci., Vol. 65, No. 1,
155 pages, (1978) J.Am.Chem.Soc., vol. 101, 4030
Page, (1979), etc. However, it is completely unknown that vesicles can be kept stable for a long period of time by combining component (B) with component (A), and this was revealed for the first time through research by the present inventors. It is something that Specific examples of the component (A) of the present invention include didecyldimethylammonium salt, didodecyldimethylammonium salt, ditetradecyldimethylammonium salt, dihexadecyldimethylammonium salt, dioctadecyldimethylammonium salt, dieicosyldimethylammonium salt, salt, didecyl
N-hydroxyethyl-N-methylammonium salt, didodecyl-N-hydroxyethyl-N-methylammonium salt, ditetradecyl-N-hydroxyethyl-N-methylammonium salt, dihexadecyl-N-hydroxyethyl-N-methylammonium salt, Examples include dioctadecyl-N-hydroxyethyl-N-methylammonium salt, dieicosyl-N-hydroxyethyl-N-methylammonium salt, and the like. Further, the counter ion of component (A) is not particularly limited, but halogen ions, methyl sulfate ions, and ethyl sulfate ions are preferred. In addition, the surfactant as component (B) of the present invention is thought to have the effect of keeping vesicles stable, and among these, (a) is a cationic surfactant, and (b) ~
(m) is a nonionic surfactant, (n) to (q)
belong to amphoteric surfactants.
Among these components (B), ethylene oxide is preferable as the alkylene oxide added to the nonionic surfactants (b) to (m). In the composition for vesicles of the present invention, the blending weight ratio of component (A) and component (B) is important;
It is necessary that the ratio of the components be in the range of 100:1 to 100:100. If the blending weight ratio is out of this range, vesicles will not be produced, or even if vesicles are produced, they will be unstable. To produce the composition for vesicles of the present invention, according to a known method, component (A) and component (B) are dissolved in a solvent that can dissolve both components, and the mixture is stirred to be homogeneous.
The solvent may then be removed. In order to obtain vesicles from the thus obtained composition for vesicles of the present invention, the composition for vesicles may be suspended in water and irradiated with ultrasound. However, this method is not limited to this method, for example, a method of dissolving the composition for vesicles in a water-soluble solvent such as ethanol, and strongly injecting this aqueous solution into water, or solubilizing it with a water-soluble surfactant, A vesicle solution can then be obtained by using a method in which the surfactant is removed by dialysis. The vesicle solution prepared by the composition for vesicles of the present invention preferably has a concentration of 1 to 50% by weight (hereinafter simply expressed as %), more preferably 5 to 30% by weight.
%. When the vesicle concentration of the solution exceeds 50%, the viscosity becomes too high, which may cause problems in the vesicle preparation process and during the use of the vesicles. Furthermore, when the concentration is less than 1%, there is no problem in preparation and use, but the cost increases in terms of transport costs and containers for the vesicle solution, which is not economical. The most reliable method currently known for identifying vesicles in a vesicle solution prepared in this manner is electron microscopy using negative staining. The negative staining method is a method in which the electron density of the hydrophilic group portion of a surfactant, etc. that can form vesicles is increased using phosphotungstic acid or uranyl acetate, and that portion is dyed black. In the present invention, vesicle formation was observed using this method. A vesicle solution containing vesicles is transparent and has good fluidity. On the other hand, when the compound does not form a vesicle but forms a multilayered structure, the solution is gel-like, cloudy, and has extremely poor fluidity.
Therefore, in a vesicle stability test (described later), for example, a vesicle solution is prepared using an ultrasonic method,
The stability of the composition for vesicles can be determined by observing the transparency and fluidity of the solution over time. In addition, nuclear magnetic resonance (NMR) is known as an auxiliary and simple method for confirming vesicles. That is, the relaxation time or absorption line width of 1 H- or 13 C-NMR differs greatly between vesicles and non-vesicles. In other words, in the case of vesicles, the relaxation time is long and the absorption linewidth is narrow and sharp, whereas in the case of non-vesicles, the relaxation time is short and the absorption linewidth is wide. however
With the NMR method, it is not possible to directly confirm the presence of a double membrane structure, which is a characteristic of vesicles, and in order to strictly confirm the presence of vesicles, observation using the above-mentioned electron microscope should be performed. EXAMPLES Next, the present invention will be explained in more detail with reference to examples, but the present invention is not limited to these examples. Example 1 Compositions for vesicles were prepared from the double-stranded quaternary ammonium salts shown in Table 1 and various surfactants, and the formation of vesicles and their stability were investigated. The results are shown in Table-1. [Preparation of composition for vesicles] 10 g of a double-stranded quaternary ammonium salt dissolved in chloroform and 1 g of a surfactant were mixed and stirred until uniform. Next, chloroform was removed using an evaporator to obtain a powder of a composition for vesicles. [Generation of vesicles and confirmation thereof] For 10 g of powder of the obtained composition for vesicles,
When 90 g of water was added and stirred, a viscous and cloudy gel-like composition was obtained. This gel composition was maintained at 60° C. and irradiated with 100 W, 25 KHz ultrasonic waves for about 1 hour.
The obtained solution was observed with an electron microscope to confirm the formation of vesicles. In addition, the solution in which vesicles were generated was almost transparent and had good fluidity. [Vesicle stability test] The vesicle solution obtained as above was stored in a constant temperature bath at 20°C for 3 months, and the state after 3 months was compared with the state immediately after production in terms of transparency and fluidity. The stability was evaluated. The evaluation criteria for vesicle generation and its stability are as follows. A: The state after storage is completely unchanged from immediately after production, and the vesicle structure is completely maintained. B: The viscosity is only slightly increased compared to immediately after production, and the vesicle structure is almost completely maintained. C: Immediately after production, the solution showed significant thickening and cloudiness, and almost no vesicle structure was present. D: Immediately after production, the solution was completely gelled and became cloudy, and no vesicle structure was observed. *: Vesicles do not form even after ultrasonic irradiation.

【表】【table】

【表】 ‖ |
O CH
(ジステアリルアミニミド)
比較例 1 表−1に示した二本鎖型第四級アンモニウム塩
10gを水90gに溶解し、実施例1の方法に準じて
ベシクルを生成させた。これを3カ月間20℃の恒
温槽で保存し、保存後の状態を調べた。21種の二
本鎖型第四級アンモニウム塩すべての場合におい
てベシクルは生成するが、3カ月の保存の後は溶
液がゲル状で白濁し、ベシクル構造が失なわれて
いた。 実施例 2 ジオクタデシルジメチルアンモニウムクロライ
ドと表−2に示された界面活性剤を用い、実施例
1の方法に従つてベシクル用組成物を調製し、該
組成物から得られるベシクルの安定性を調べた。
この結果を表−2に示す。
[Table] ‖ |
O CH 3
(distearylaminimide)
Comparative Example 1 Double-stranded quaternary ammonium salt shown in Table-1
10 g was dissolved in 90 g of water, and vesicles were produced according to the method of Example 1. This was stored in a constant temperature bath at 20°C for 3 months, and its condition after storage was examined. Vesicles were formed in all 21 double-stranded quaternary ammonium salts, but after 3 months of storage, the solution became gel-like and cloudy, and the vesicle structure was lost. Example 2 A composition for vesicles was prepared according to the method of Example 1 using dioctadecyldimethylammonium chloride and the surfactant shown in Table 2, and the stability of vesicles obtained from the composition was investigated. Ta.
The results are shown in Table-2.

【表】 実施例 3 表−3に示す合計12種類の二本鎖型第四級アン
モニウム塩と、実施例1で用いた3種類の界面活
性剤をそれぞれ組み合わせて、実施例1の方法に
準じて合計36種類のベシクル用組成物を調製し、
該組成物から得られるベシクルの安定性を調べ
た。この結果を表−3に示す。
[Table] Example 3 A total of 12 types of double-stranded quaternary ammonium salts shown in Table 3 were combined with the three types of surfactants used in Example 1, and the methods of Example 1 were followed. A total of 36 types of vesicle compositions were prepared.
The stability of vesicles obtained from the composition was investigated. The results are shown in Table-3.

【表】 実施例 4 ジオクタデシルジメチルアンモニウムクロライ
ドと実施例1で用いた界面活性剤とを、表−4に
示す配合比率で混合し、実施例1の方法に従つて
合計39種のベシクル用組成物を調製した。この組
成物について、実施例1と同様にしてベシクル生
成及びその安定性を調べた。この結果を表−4に
示す。
[Table] Example 4 Dioctadecyldimethylammonium chloride and the surfactant used in Example 1 were mixed at the blending ratio shown in Table 4, and a total of 39 types of vesicle compositions were prepared according to the method of Example 1. I prepared something. Regarding this composition, vesicle formation and its stability were investigated in the same manner as in Example 1. The results are shown in Table 4.

【表】【table】

【表】【table】

Claims (1)

【特許請求の範囲】 1 次の2成分(A)及び(B)を含有し、(A)成分と(B)成
分の重量比が100:1〜100:100であるベシクル
用組成物。 (A) 一般式() 式中、各記号は次のものを意味する。 R1及びR2:炭素数10〜24の炭化水素基 R3及びR4:炭素数1〜4の炭化水素基若しくは
ヒドロキシ炭化水素基又はベンジル基 X:第四級アンモニウムイオンの対イオンとな
るアニオン で表わされる二本鎖型第四級アンモニウム塩 (B) 一種又は二種以上の、次の式(a)〜(q) R6O(AO)oH (b) HO(AO)p(C3H6O)q(AO)r (d) R6COO(AO)oR10 (g) R15NH(A)tCOOM (p) 式中、各記号は次のものを示す。 R5:炭素数1〜4の炭化水素基若しくはヒドロ
キシ炭化水素基又はベンジル基 R6:炭素数8〜36の炭化水素基 R7:炭素数5〜23の炭化水素基 R8、R9及びR10:水素原子又は炭素数6〜24のア
シル基(ただし、一分子中にR7とR8を両方含
む場合、そのうち少なくとも一方は水素原子で
ある) R11及びR12:水素原子又は炭素数6〜24の炭化
水素基(ただし、少なくとも一方は水素原子で
ある) R13:炭素数9〜23の炭化水素基 R14:炭素数1〜24の炭化水素基若しくはヒドロ
キシ炭化水素基又はベンジル基 R15、R16及びR17:炭素数1〜24の炭化水素基 A:炭素数2〜4のアルキレン基 M:アルカリ金属イオン、モノエタノールアンモ
ニウムイオン、ジエタノールアンモニウムイオ
ン又はトリエタノールアンモニウムイオン l,m及びn:0又は1〜150の整数 p,q及びr:1〜150の整数 t:1〜4の整数 X :前記と同じ で表わされる化合物群から選ばれた界面活性剤。 2 (A)成分及び(B)成分中、対イオンX がハロゲ
ンイオン、メチル硫酸イオン又はエチル硫酸イオ
ンである特許請求の範囲第1項記載のベシクル用
組成物。
[Scope of Claims] 1. A composition for vesicles containing the following two components (A) and (B), wherein the weight ratio of component (A) to component (B) is 100:1 to 100:100. (A) General formula () In the formula, each symbol means the following. R 1 and R 2 : Hydrocarbon group having 10 to 24 carbon atoms R 3 and R 4 : Hydrocarbon group having 1 to 4 carbon atoms or hydroxy hydrocarbon group or benzyl group X: Serves as a counter ion for quaternary ammonium ion Double-stranded quaternary ammonium salt (B) represented by an anion, one or more of the following formulas (a) to (q) R 6 O (AO) o H (b) HO (AO) p (C 3 H 6 O) q (AO) r H (d) R 6 COO (AO) o R 10 (g) R 15 NH (A) t COOM (p) In the formula, each symbol represents the following. R 5 : Hydrocarbon group having 1 to 4 carbon atoms, hydroxy hydrocarbon group or benzyl group R 6 : Hydrocarbon group having 8 to 36 carbon atoms R 7 : Hydrocarbon group having 5 to 23 carbon atoms R 8 , R 9 and R 10 : Hydrogen atom or acyl group having 6 to 24 carbon atoms (however, if one molecule contains both R 7 and R 8 , at least one of them is a hydrogen atom) R 11 and R 12 : Hydrogen atom or carbon Hydrocarbon group having 6 to 24 carbon atoms (at least one of them is a hydrogen atom) R 13 : Hydrocarbon group having 9 to 23 carbon atoms R 14 : Hydrocarbon group having 1 to 24 carbon atoms, hydroxy hydrocarbon group, or benzyl Groups R 15 , R 16 and R 17 : Hydrocarbon group having 1 to 24 carbon atoms A: Alkylene group having 2 to 4 carbon atoms M: alkali metal ion, monoethanol ammonium ion, diethanol ammonium ion or triethanol ammonium ion l, m and n: 0 or an integer of 1 to 150 p, q and r: an integer of 1 to 150 t: an integer of 1 to 4 X: a surfactant selected from the group of compounds represented by the same as above. 2. The composition for vesicles according to claim 1, wherein the counter ion X in component (A) and component (B) is a halogen ion, a methyl sulfate ion, or an ethyl sulfate ion.
JP58181629A 1983-09-29 1983-09-29 Composition for vesicle Granted JPS6072831A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP58181629A JPS6072831A (en) 1983-09-29 1983-09-29 Composition for vesicle
GB08422628A GB2147263B (en) 1983-09-29 1984-09-07 Compositions for making vesticles
DE19843435516 DE3435516A1 (en) 1983-09-29 1984-09-27 MASSES FOR VESICLE TRAINING
FR8414910A FR2552679B1 (en) 1983-09-29 1984-09-28 VESICULAR COMPOSITIONS BASED ON QUATERNARY AMMONIUM SALT AND SURFACTANT

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58181629A JPS6072831A (en) 1983-09-29 1983-09-29 Composition for vesicle

Publications (2)

Publication Number Publication Date
JPS6072831A JPS6072831A (en) 1985-04-24
JPH0326166B2 true JPH0326166B2 (en) 1991-04-10

Family

ID=16104113

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58181629A Granted JPS6072831A (en) 1983-09-29 1983-09-29 Composition for vesicle

Country Status (4)

Country Link
JP (1) JPS6072831A (en)
DE (1) DE3435516A1 (en)
FR (1) FR2552679B1 (en)
GB (1) GB2147263B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5234767A (en) * 1987-03-13 1993-08-10 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US4855090A (en) * 1987-03-13 1989-08-08 Micro-Pak, Inc. Method of producing high aqueous volume multilamellar vesicles
US5628936A (en) * 1987-03-13 1997-05-13 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US4942038A (en) * 1987-03-13 1990-07-17 Micro Vesicular Systems, Inc. Encapsulated humectant
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
US4917951A (en) * 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US5023086A (en) * 1987-03-13 1991-06-11 Micro-Pak, Inc. Encapsulated ionophore growth factors
US4853228A (en) * 1987-07-28 1989-08-01 Micro-Pak, Inc. Method of manufacturing unilamellar lipid vesicles
US5019392A (en) * 1988-03-03 1991-05-28 Micro-Pak, Inc. Encapsulation of parasiticides
US5019174A (en) * 1988-03-03 1991-05-28 Micro Vesicular Systems, Inc. Removing oil from surfaces with liposomal cleaner
US5104736A (en) * 1988-03-03 1992-04-14 Micro-Pak, Inc. Reinforced paucilamellar lipid vesicles
US5160669A (en) * 1988-03-03 1992-11-03 Micro Vesicular Systems, Inc. Method of making oil filled paucilamellar lipid vesicles
US5032457A (en) * 1988-03-03 1991-07-16 Micro Vesicular Systems, Inc. Paucilamellar lipid vesicles using charge-localized, single chain, nonphospholipid surfactants
DE4107152C2 (en) * 1991-03-06 1994-03-24 Gregor Cevc Preparations for non-invasive administration of antidiabetics
DE4107153A1 (en) * 1991-03-06 1992-09-10 Gregor Cevc Compsns. for application of active agents
US5164191A (en) * 1991-02-12 1992-11-17 Micro Vesicular Systems, Inc. Lipid vesicles having an alkyd as a wall-forming material
US5213805A (en) * 1991-07-25 1993-05-25 Micro Vesicular Systems, Inc. Lipid vesicles having n,n-dimethylamide derivatives as their primary lipid
US5405615A (en) * 1991-09-17 1995-04-11 Micro Vesicular Systems, Inc. Sucrose distearate lipid vesicles
US5260065A (en) * 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
US5643600A (en) * 1991-09-17 1997-07-01 Micro-Pak, Inc. Lipid vesicles containing avocado oil unsaponifiables
US5439967A (en) * 1991-09-17 1995-08-08 Micro Vesicular Systems, Inc. Propylene glycol stearate vesicles
FR2687313A1 (en) * 1992-02-17 1993-08-20 Oreal Dispersion of vesicles based on betaines and cosmetic or pharmaceutical compositions containing this dispersion.
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
DE69527206T2 (en) * 1994-09-30 2003-02-27 Inex Pharmaceuticals Corp., Vancouver AGENT FOR INSERTING POLYANIONIC MATERIALS IN CELLS
US7749520B2 (en) 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50105997A (en) * 1974-01-11 1975-08-21
JPS5394694A (en) * 1977-01-29 1978-08-18 Lion Fat Oil Co Ltd Fiber softening composition
JPS53134784A (en) * 1977-04-28 1978-11-24 Kao Corp Production of small hollow cell-containing material consisting of double layers of surface active agent
JPS5626071A (en) * 1979-06-05 1981-03-13 Procter & Gamble Liquid fabric conditioning composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753990A (en) * 1972-01-17 1973-08-21 Procter & Gamble Phenylbismuth bis(2-pyridinethiol 1-oxide)
FR2315991A1 (en) * 1975-06-30 1977-01-28 Oreal METHOD OF MANUFACTURING AQUEOUS DISPERSIONS OF LIPID SPHERULES AND CORRESPONDING NEW COMPOSITIONS
FR2416008A1 (en) * 1978-02-02 1979-08-31 Oreal LIPOSOME LYOPHILISATES
ATE8584T1 (en) * 1980-01-16 1984-08-15 Hans Georg Prof. Dr. Weder METHOD AND DIALYZER EQUIPMENT FOR THE MANUFACTURE OF BILAYER VESICLES AND USE OF THE BILAYER VESICLES.
GR77320B (en) * 1980-12-22 1984-09-11 Procter & Gamble
EP0067635A3 (en) * 1981-06-15 1984-02-22 THE PROCTER & GAMBLE COMPANY Shampoo compositions
EP0102324A3 (en) * 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipids and surfactants in an aqueous medium

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50105997A (en) * 1974-01-11 1975-08-21
JPS5394694A (en) * 1977-01-29 1978-08-18 Lion Fat Oil Co Ltd Fiber softening composition
JPS53134784A (en) * 1977-04-28 1978-11-24 Kao Corp Production of small hollow cell-containing material consisting of double layers of surface active agent
JPS5626071A (en) * 1979-06-05 1981-03-13 Procter & Gamble Liquid fabric conditioning composition

Also Published As

Publication number Publication date
FR2552679B1 (en) 1993-06-11
GB2147263A (en) 1985-05-09
FR2552679A1 (en) 1985-04-05
JPS6072831A (en) 1985-04-24
GB8422628D0 (en) 1984-10-10
GB2147263B (en) 1987-03-25
DE3435516A1 (en) 1985-04-18

Similar Documents

Publication Publication Date Title
JPH0326166B2 (en)
JPS63196510A (en) Liposome preparation embedding antitumor agent
DE60126433T2 (en) PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR USE WITH WEICHGELATINE FORMULATIONS
JPS6156016B2 (en)
JPH0326165B2 (en)
JPS61218515A (en) Manufacture of vesicle by microemulsion
JP2009507891A (en) Antibacterial formulation containing octenidine dihydrochloride encapsulated in liposomes
FR2597367A1 (en) PROCESS FOR FACILITATING THE FORMATION OF LIPID SPHERULES DISPERSION IN AN AQUEOUS PHASE AND FOR IMPROVING THEIR STABILITY AND THEIR ENCAPSULATION RATE, AND CORRESPONDING DISPERSIONS.
JPH08268915A (en) Base for pharmaceutical preparation
TW201124425A (en) Parenteral formulations of gemcitabine derivatives
JPWO2008096779A1 (en) C70-containing liposome, method for producing the same, and use thereof
US20130251629A1 (en) Nanoemulsion for the delivery of at least two agents of interest
JP5588619B2 (en) pH-responsive liposome
CN103108625A (en) Parenteral formulations of elacytarabine derivatives
Ryan et al. The preparation and characterization of liposomes containing X-ray contrast agents
DE3882984T2 (en) PRODUCTION OF A SOLUTION CONSISTING OF A PHARMACOLOGICAL ACTIVE SUBSTANCE AND A LIPID.
JP2000229815A (en) Liposome and its utilization
US20050143476A1 (en) Emulsion composite
KR20190035472A (en) Method of producing positively charged electric charge niosome and electric charge niosome
JPS6072829A (en) Composition for vesicle
JPS6075434A (en) Composition for vesicle
JPH11500413A (en) Paramagnetic complexes of N-alkyl-N-hydroxylamides of organic acids and emulsions containing them for magnetic resonance imaging (MRI)
JPH05186372A (en) Fat emulsion and contrast medium for mri diagnosis
JPS60136508A (en) Composition for vesicle
JPH0649145B2 (en) Method for producing bilayer vesicles